Halozyme Corp (HALO) - Gross Profitability Margin

Official company branding of Halozyme Corp (HALO)

Steady demand from pharma behemoths for patent extensions is expanding sales markets, as evidenced by the performance dynamics. The gross margin percentage illustrates the efficiency of the licensing model for unique, patent-protected injection methods. Industry confidence in Halozyme Therapeutics (HALO) innovations that simplify cancer therapy supports growth, and 76.10 shapes the current metric, determining the asset's valuation vector.

Gross Profitability: Halozyme (HALO) for 07/04/2022 - 11/20/2026

Comprehensive metric breakdowns and analytics for Halozyme Therapeutics (HALO)

- stock value and consensus price forecast:
Summary company analysis:Halozyme - HALO
Signature product of Halozyme Corp

Gross margin measures the profit share after deducting direct production costs, reflecting the efficiency of cost-of-goods-sold management. For Halozyme Therapeutics (HALO), this metric confirms the resilience of its royalty-based model, rendering the relative gross margin an indicator of protection against commodity shocks. The trend captured by this curve allows for the timely detection of sanctions' impact on partner supply chains. Consistently high profitability here testifies to the high quality of the business's intellectual capital.

Direct competitors

Gross Profit Margin BeiGene Ltd. (ONC)|Gross Profitability RevMed|Gross Return on Sales AAPG (Ascentage Pharma Group)|Gross Margin CGON|UroGen Pharma - Gross Return on Sales|Bicara Therapeutics - Return on Gross Profit|Gross Margin Personalis Inc PSNL|Erasca Oncology - Gross Margin|Gross Profit Rate DCTH (Delcath Corp)|YMAB: Gross Margin|AURA - Return on Sales by Gross Profit|CADL (Candel Therapeutics Inc.) - Gross Margin|Gross Return on Sales ARAY (Accuray)|Return on Gross Profit SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Gross Profit Margin|Gross Profitability Citius Oncology, Inc. CTOR|HURA - Return on Gross Profit|protaratx.com - Gross Margin|FATE - Gross Margin|WHWK: Gross Margin|TScan Therapeutics (TCRX) - Gross Margin|Gross Profitability Champions Oncology|Gross Profitability XBIT|Gross Margin CVM|Return on Gross Profit OS Therapies Inc. OSTX|Gross Profitability Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Gross Profit Margin|ANL - Gross Profitability|Gross Profit Margin verupharma.com|TPST: Gross Margin|XLO - Return on Sales by Gross Profit|Gross Profitability Renovaro|Gross Margin muraloncology.com|Gross Margin KAPA|Return on Sales by Gross Profit OnKure Therapeutics, Inc.|Gross Margin GDTC (w2.cytomed.sg)|CRIS - Return on Gross Profit|Apollomics - Gross Margin|Tharimmune Corp (THAR) - Return on Gross Profit|ADVB: Gross Margin|Return on Gross Profit Genprex|CLDI (Calidi Biotherapeutics, Inc.) - Gross Margin|Gross Return on Sales SBFM (Sunshine Biopharma)|Gross Profitability Xenetic Bio (XBIO)|Gross Profitability SLRX (Salarius Pharma)|Kitov Pharma - Return on Gross Profit|American Oncology Network (AONC) - Gross Profit Margin|BeiGene - Gross Margin|Checkpoint Therapeutics, Inc. (CKPT) - Return on Gross Profit|ELEV (Elevation Oncology, Inc.) - Return on Gross Profit|iCAD Inc. - Gross Profit Rate|Return on Gross Profit IKNA|Gross Margin notablelabs.com|Return on Gross Profit VIRX (Viracta Therapeutics Inc.)|MOR - Gross Profit Margin|Gross Profitability NAYA Biosciences NAYA|AAPGV - Return on Gross Profit